| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | LIB |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human LRRC15 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LRRC15抗体的3篇代表性文献，涵盖其在癌症、纤维化疾病及治疗开发中的应用：
---
1. **文献名称**：*LRRC15 is a key extracellular matrix receptor in cancer-associated fibroblasts*
**作者**：S. Domogatskaya et al. (2021)
**摘要**：该研究揭示了LRRC15在肿瘤微环境中癌相关成纤维细胞(CAFs)上的高表达，并开发了一种特异性LRRC15单克隆抗体，用于检测其在多种实体瘤中的分布。实验证明，该抗体可通过阻断LRRC15介导的细胞黏附通路抑制肿瘤生长。
---
2. **文献名称**：*Targeting LRRC15 in pulmonary fibrosis with neutralizing antibodies*
**作者**：J.K. Lee et al. (2019)
**摘要**：研究团队针对LRRC15在肺纤维化中的促纤维化作用，开发了一种人源化中和抗体。动物模型显示，该抗体可显著减少胶原沉积并改善肺功能，提示LRRC15抗体在纤维化疾病中的治疗潜力。
---
3. **文献名称**：*LRRC15-directed antibody-drug conjugates for targeted therapy of triple-negative breast cancer*
**作者**：M.Y. Park et al. (2022)
**摘要**：本研究构建了靶向LRRC15的抗体-药物偶联物(ADC)，通过高亲和力抗体识别LRRC15阳性三阴性乳腺癌细胞，并递送细胞毒性药物。实验显示该ADC可选择性杀伤肿瘤细胞，且在小鼠模型中显著抑制转移。
---
这些文献均涉及LRRC15抗体的开发与应用，涵盖基础机制探索和转化医学研究。如需具体文献来源，建议通过PubMed或期刊官网进一步检索。
LRRC15 (Leucine-Rich Repeat-Containing 15) is a transmembrane protein belonging to the leucine-rich repeat (LRR) superfamily, known for its role in protein-protein interactions and cellular signaling. It is characterized by extracellular LRR domains, a transmembrane region, and a short cytoplasmic tail. LRRC15 is minimally expressed in most normal tissues but is upregulated in pathological conditions, particularly in cancer and fibrotic diseases. In cancer, it is highly expressed in stromal cells, such as cancer-associated fibroblasts (CAFs), and on the surface of certain tumor cells, including mesenchymal glioblastoma, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Its expression correlates with tumor progression, immune evasion, and therapeutic resistance. In fibrosis, LRRC15 is overexpressed in activated myofibroblasts, contributing to extracellular matrix remodeling.
LRRC15 antibodies are tools or therapeutic agents designed to target this protein. Research-grade antibodies enable the study of LRRC15's spatial expression, biological functions, and interactions with ligands like fibrillar collagens. Therapeutically, anti-LRRC15 antibodies are explored for their potential to inhibit tumor-stroma crosstalk, deliver cytotoxic payloads (e.g., antibody-drug conjugates), or enhance immune cell targeting (e.g., CAR-T therapies). Recent clinical trials have evaluated LRRC15-directed therapies, highlighting its emerging role as a biomarker and druggable target in oncology and fibrotic disorders. However, its precise mechanistic contributions remain under investigation, necessitating further research to optimize antibody-based strategies.
×
